Competitor Analysis: Immunocytokines
Cytokine-engineering as a measure to reduce dose-limiting toxicities of immunocytokines
The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety.
The present Competitive Intelligence report aboutImmunocytokinesprovides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The development of recombinant cytokines, or mainly antibody-cytokine fusion proteins, has been characterized by many drawbacks from dose-limiting toxicities. Over several years, development of new cytokines has stagnated, but recent R&D work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety.
The present Competitive Intelligence report aboutImmunocytokinesprovides a competitor evaluation in the field of recombinant fusion proteins of a targeting moiety and a human cytokine as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of recombinant immunocytokines with first and second generation cytokine payloads. In addition, the report lists company-specific R&D pipelines of Immunocytokines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Immunocytokines with TNF as Payload
Immunocytokines with First-Generation Interleukin-2 as Payload
Immunocytokines with Second-Generation Interleukin-2 as Payload
Immunocytokines with Interleukin-10 as Payload
Immunocytokines with Interleukin-12 as Payload
Immunocytokines with Interleukin-15 as Payload
Immunocytokines with Interferon as Payload
Corporate Immunocytokine R&D Pipelines
Immunocytokines with First-Generation Interleukin-2 as Payload
Immunocytokines with Second-Generation Interleukin-2 as Payload
Immunocytokines with Interleukin-10 as Payload
Immunocytokines with Interleukin-12 as Payload
Immunocytokines with Interleukin-15 as Payload
Immunocytokines with Interferon as Payload
Corporate Immunocytokine R&D Pipelines
More Publications
Competitor Analysis: B7 – CD28/CTLA-4 Pathway
US$ 370.00
July 2012
35 pages
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
US$ 335.00
February 2013
43 pages
Competitor Analysis: Neurotrophic Growth Factors
US$ 460.00
December 2009
38 pages
Competitor Analysis: PSMA & PSA Targeted Therapy
US$ 172.50
January 2010
18 pages
Competitor Analysis: Growth Factors for Bone, Dental, Cartilage and Tendon Repair
US$ 345.00
December 2009
42 pages
